Scandion Oncology receives final approval from the Danish Medicines Agency for start of clinical Phase II trial in patients with drug resistant metastatic colorectal cancer

Scandion Oncology A/S (“Scandion Oncology”) today announces that the company has received final approval from the Danish Medicines Agency for start of a clinical Phase II trial with the drug candidate SCO-101 in combination with chemotherapy in patients with drug resistant metastatic colorectal cancer. The study is conducted in two parts. The first interim results from this first part are expected in Q2 2020 and the final study is expected to be available by the end of 2020.

The release as fetched from its publisher. scandiononcology.com ↗